NSAID-GASTROPATIYA RIVOJLANISHI XAVF OMILLARI VA ULARNING PROFILAKTIKASI YO'LLARI
##article.subject##:
NSYQP-gastropatiyasi, xavf omillari, oldini olish.##article.abstract##
ANNOTATSIYA.
Nosteroid yallig'lanishga qarshi preparatlarning (NSYQP) keng qo'llanilishi aniq yallig'lanishga qarshi va og'riq qoldiruvchi ta'siriga bog'liq. Ularning uzoq muddatli qo'llanilishi gastroduodenal zonaning shilliq qavatini shikastlanishi va oshqozon-ichak traktidan qon ketishining rivojlanishi kabi bir qator salbiy ta'sirlar bilan bog'liq. Ushbu maqolada NSYQP-gastropatiyasi rivojlanishining xavf omillari tahlil qilingan, davolash taktikasi va oldini olish variantlari baholangan, ish natijalari keltirilgan.
Библиографические ссылки
Balabantseva A.P., Karateev A.E. Frequency and clinical and endoscopic features of combined NSAID-induced gastrointestinal injuries // Modern rheumatology. 2018; 12(4): 95-1002. (in Russ).
Ivashkin V.T. et al. Clinical guidelines for the diagnosis and treatment of erosive and ulcerative lesions of the stomach and duodenum caused by non-steroidal anti-inflammatory drugs. Clinical recommendations. M., 2014. (in Russ).
Karateev A.E. NSAID gastropathy: Dynamics over 12 years // Scientific and practical rheumatology. 2011; 3, 20-24. (in Russ).
Karateev A.E. and others. Clinical recommendations “Rational use of non-steroidal anti-inflammatory drugs (NSAIDs) in clinical practice”. Modern rheumatology. 2015; 9 (1): 4–23. (in Russ).
Kolesnikov I.Yu. Gastropathy during treatment with non-steroidal anti-inflammatory drugs. Nurse. 2018; 20(8):40-43. (in Russ).
Muravyov Yu.V., Lebedeva V.V. Side effects of NSAIDs and the intestines: a review Russian Gastroenterological Journal. 2000; 4: 78-83. (in Russ).
Nasonov E.L., Ivashkin V.T., Yakhno N.N. and others. Rational use of non-steroidal anti-inflammatory drugs based on the results of a meeting of a group of experts. Scientific-practical. rheumatol. 2017; 55 (4): 452–6. (in Russ).
Nasonov E.L. The use of non-steroidal anti-inflammatory drugs: therapeutic prospects. Russian Med. Magazine. 2002; T. 10. 4: 264-266. (in Russ)
Pakhomova I.G. New opportunities in minimizing the risk of NSAID-induced gastropathy. Breast Cancer. 2014; 10: 772. (in Russ).
Khudarova A., Osadchuk M. NSAID gastropathy: predicting the course and outcomes. Doctor. –2018; 29 (5): 17–23. DOI: 10.29296/25877305-2018-05-04 (in Russ).
Sheptulin A.A., Lapina T.L., Kaibysheva V.O. New in the study of Helicobacter pylori infection and the main provisions of the Maastricht-V Conciliation Meeting (2016). Ros. magazine gastroenterol, hepatol. and coloproctol. 2017; 27 (1): 35–43. (in Russ).
Carli D., Pires R., Rohde S. et al. Peptic ulcer frequency differences related to Н. pylori or aines. Arq. Gastroenterol. 2015; 52 (1): 46–9.
Lanas A., Tornero J., Zamorano J. Assessment of gastrointestinal and сardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann. Rheum. Dis. 2010; 69 (8): 1453–8.
Straube S., Tramèr M., Moore R. et al. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol.2009; 9: 41.
